Pancreatic Cancer Research

ResearcherChiba UniversityNo recent work listed

Osamu Yokosuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1763-9439; OpenAlex author ID A5102927536, A5110892274. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper

Papers 9

  1. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Co-author DOI 10.1038/bjc.2016.295↗
  2. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer. Last author DOI 10.1002/jmri.24939↗
  3. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-013-2368-6↗
  4. Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stres… Last author DOI 10.3892/or.2014.3533↗
  5. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. Last author DOI 10.1007/s00535-012-0684-y↗
  6. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Co-author DOI 10.1016/j.radonc.2012.08.009↗
  7. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Last author DOI 10.1007/s00280-010-1311-3↗
  8. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Last author DOI 10.1016/j.ijrobp.2010.01.027↗
  9. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rintaro Mikata · 5 shared papers, 2013–2016 · strength 0.20
  2. Masaru Miyazaki · 3 shared papers, 2013–2016 · strength 0.13
  3. Hideyuki Yoshitomi · 2 shared papers, 2015–2016 · strength 0.09
  4. Masayuki Ohtsuka · 2 shared papers, 2015–2016 · strength 0.09
  5. Taketo Yamaguchi · 3 shared papers, 2011–2014 · strength 0.08
  6. Kentaro Sudo · 3 shared papers, 2011–2014 · strength 0.08
  7. Jo Kurosawa · 2 shared papers, 2013–2015 · strength 0.08
  8. Tadamichi Denda · 2 shared papers, 2011 · strength 0.05
  9. Kazuyuki Sogawa · 1 shared paper, 2016 · strength 0.05
  10. Mamoru Satoh · 1 shared paper, 2016 · strength 0.05
  11. Shigetsugu Takano · 1 shared paper, 2016 · strength 0.05
  12. Fumio Nomura · 1 shared paper, 2016 · strength 0.05
  13. Xia Jiang · 1 shared paper, 2014 · strength 0.04
  14. Kazuhiko Oonishi · 1 shared paper, 2012 · strength 0.03
  15. Tadashi Kamada · 1 shared paper, 2012 · strength 0.03
  16. Shigeru Yamada · 1 shared paper, 2012 · strength 0.03
  17. Shoji Nakamori · 1 shared paper, 2011 · strength 0.02
  18. Shinichi Ohkawa · 1 shared paper, 2011 · strength 0.02
  19. Tosiya Shun Sato · 1 shared paper, 2011 · strength 0.02
  20. Narikazu Boku · 1 shared paper, 2011 · strength 0.02
  21. Akihiro Funakoshi · 1 shared paper, 2011 · strength 0.02
  22. Junji Furuse · 1 shared paper, 2011 · strength 0.02
  23. Fuminori Moriyasu · 1 shared paper, 2011 · strength 0.02
  24. H. Ueno · 1 shared paper, 2011 · strength 0.02
  25. Takuji Okusaka · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.